-
Bradykinin (BA5201): Technical Use Guide for Vascular Assays
2026-07-06
Bradykinin (BA5201) is a potent endothelium-dependent vasodilator peptide used for scientific research focused on cardiovascular function, vascular permeability, and pain/inflammation signaling. This guide outlines technical handling, assay setup, and known limitations to support robust experimental outcomes. This product is not suitable for clinical, diagnostic, or long-term storage applications.
-
Bafilomycin C1 in Phenotypic Screening: Precision Tools for
2026-07-06
Discover how Bafilomycin C1, a gold-standard vacuolar H+-ATPases inhibitor, empowers translational researchers to interrogate autophagy, lysosomal function, and cellular toxicity in cutting-edge disease models. Bridging mechanistic insight with workflow strategy, this article details the rationale, protocol parameters, and strategic advantages of Bafilomycin C1 in high-content phenotypic screens, with a special focus on iPSC-derived cell systems and deep learning approaches for cardiotoxicity detection.
-
GI 254023X: Advanced ADAM10 Inhibitor for Barrier & Signal R
2026-07-05
GI 254023X enables precise, high-selectivity inhibition of ADAM10, empowering researchers to dissect signaling, apoptosis, and barrier function with unparalleled specificity. Its robust performance in cell and mouse models makes it an indispensable tool for vascular and immunological research workflows.
-
Honokiol in Immunometabolism: Protocols and Troubleshooting
2026-07-04
Honokiol, a potent NF-κB pathway inhibitor, empowers researchers to dissect inflammation and tumor microenvironment dynamics with precision. This guide details stepwise workflows, key innovations from recent immunometabolic studies, and troubleshooting strategies so you can maximize the scientific impact of Honokiol in advanced experimental models.
-
Gut Dysbiosis Drives Prostate Cancer via NF-κB-IL6-STAT3 Axi
2026-07-03
Zhong et al. reveal that antibiotic-driven gut dysbiosis accelerates prostate cancer growth and docetaxel resistance through the NF-κB-IL6-STAT3 signaling axis, linking intestinal microbial imbalances to extraintestinal tumor progression. These findings offer mechanistic insight and reinforce the relevance of STAT3 pathway inhibition in cancer biology research.
-
SU6656 Src Tyrosine Kinases Inhibitor: Protocols and Benchma
2026-07-03
SU6656 is a selective Src tyrosine kinases inhibitor advancing ex vivo platelet production and radiotherapy sensitization. Evidence supports its role in enhancing megakaryocyte polyploidization and potentiating radiation-induced antiangiogenic effects. This article details protocols, limitations, and cross-domain research implications.
-
Endothelial Endoglin Drives Astrocyte Reactivity in Alzheime
2026-07-02
This study uncovers a mechanistic link between cerebrovascular endothelial cells and astrocyte activation in Alzheimer’s disease, mediated by the protein endoglin delivered via extracellular vesicles. The findings highlight a new neurovascular signaling axis and identify endoglin as a promising biomarker and therapeutic target for early Alzheimer’s pathophysiology.
-
Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding
2026-07-02
Oliveira et al. (2025) reveal that naturally occurring angiotensin peptides, including fragments like H2N-Ile-His-Pro-OH, enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. This work expands the functional landscape of renin-angiotensin system peptides, suggesting new mechanistic links between cardiovascular signaling and viral pathogenesis.
-
Berberrubine Chloride: Multi-Pathway Mechanisms in Hyperuric
2026-07-01
Explore the multifaceted bioactivity of Berberrubine chloride, a potent 9-hydroxy-10-methoxy isoquinoline alkaloid, as an anti-hyperuricemia agent and cancer research tool. This article provides a deep dive into its mechanisms, translational relevance, and unique advantages for advanced preclinical workflows.
-
Calpain Inhibitor II, ALLM: Precision Tools for Cancer Prote
2026-07-01
Calpain Inhibitor II, ALLM from APExBIO empowers researchers to dissect cancer-related protease mechanisms with quantitative precision. Its ability to robustly inhibit calpains and cathepsins unlocks reproducible apoptosis and protease inhibition workflows in leukemia, lymphoma, and advanced breast cancer models.
-
Cardiovascular Outcomes of Ertugliflozin: Implications for A
2026-06-30
The VERTIS CV trial assessed the cardiovascular safety of ertugliflozin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The study found ertugliflozin to be noninferior to placebo regarding major adverse cardiovascular events, with nuanced findings for heart failure and renal endpoints. These results refine the landscape for antihypertensive strategy development and highlight the need for mechanistically differentiated models, such as those employing ACE inhibitors like fosinopril sodium.
-
CAFs-Derived Fatty Acids Promote Oral Cancer via Lipid Rafts
2026-06-30
This study uncovers how cancer-associated fibroblasts (CAFs) in the tumor microenvironment secrete free fatty acids (FFAs) that are incorporated into oral squamous cell carcinoma (OSCC) cell membranes, fostering lipid raft formation and activating oncogenic PI3K/AKT signaling. These findings clarify a metabolic axis driving OSCC progression and highlight lipid raft assembly as a promising therapeutic target.
-
Re-Evaluating ACE Inhibitor Selectivity: Insights from Amino
2026-06-29
This article reviews the comprehensive evaluation of ACE inhibitors and related metallopeptidase inhibitors on cell-surface aminopeptidases N, A, and W, as published by Tieku and Hooper. The study clarifies the specificity and cross-reactivity of key inhibitors, highlighting implications for cardiovascular research and the design of selective experimental tools.
-
Sulforaphane Inhibits NLRP3 Inflammasome in Ulcerative Colit
2026-06-29
This study demonstrates that sulforaphane, a natural isothiocyanate, reduces oxidative stress and inhibits NLRP3 inflammasome activation in a dextran sodium sulfate (DSS)-induced mouse model of ulcerative colitis. The findings provide mechanistic clarity for sulforaphane’s anti-inflammatory action and highlight its potential as a tool for modeling oxidative stress and inflammasome pathways in inflammatory disease research.
-
METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC
2026-06-28
Wang et al. uncover a novel METTL16-SENP3-LTF signaling pathway that enables hepatocellular carcinoma (HCC) cells to resist ferroptosis by modulating iron metabolism. This mechanistic insight reveals promising targets for sensitizing HCC to ferroptosis-based therapies, with direct implications for translational cancer research.